Dr Aris Angelis is an Assistant Professor in Health Economics with the Department of Health Services Research and Policy at the London School of Hygiene and Tropical Medicine (LSHTM), and a Visiting Fellow with the Department of Health Policy at LSE. Prior joining LSHTM, Aris worked for 10 years with the Medical Technologies Research Group at LSE Health.
Aris’ academic interests are in the areas of pharmaceutical policy, health technology assessment (HTA), and drug regulation, with a lot of his work focusing on methodological research around the evaluation of new medical technologies. At LSHTM, Aris is leading the development of a research programme for assessing the value of new oncology products at an early stage by applying decision analytic modelling techniques, while collaborating with the Center for Health Policy & Outcomes at the Memorial Sloan Kettering Cancer Center. At LSE Aris is involved with the EU funded project IMPACT-HTA, co-leading the research activities of WP7 on multi-criteria value methods where he is working towards a new value framework for medicines in collaboration with different HTA bodies. He is also involved in a project initiative with the European Society for Medical Oncology (ESMO), co-leading research activities towards the development of a new value framework for cancer medicines, involving large-scale preference elicitation studies with different stakeholders. Aris has undertaken contracted research, training and advisory work for the European Commission, the World Health Organisation, national health ministries and various biopharmaceutical organisations.
Aris received his Doctor of Philosophy (PhD) in Pharmaceutical Policy and Economics from the Department of Social Policy (LSE Health) at LSE. His PhD investigated the development and application of a methodological framework based on Multiple Criteria Decision Analysis (MCDA) for assessing the value of new medical technologies in the context of HTA, to inform resource allocation decisions and incentivise socially desirable R&D investments. He also holds an MSc in International Health Policy from the LSE, an MSc in Biopharmacy from King’s College London and a BSc in Biochemistry from Imperial College London.